10-Q: NovelStem International Corp. Q2 2026 Financials Show Continued Losses

NovelStem International Corp. reported a net loss of $140,816 for the six months ended June 30, 2026, with current liabilities significantly exceeding current assets, highlighting ongoing liquidity concerns.

Summary

• NovelStem International Corp. reported a net loss of $140,816 for the six months ended June 30, 2026, compared to a net income of $2,546,625 in the same period of 2025.
• The company's current assets stood at $64,687 as of June 30, 2026, while current liabilities were $2,097,158, indicating a significant liquidity shortfall.
• The accumulated deficit has grown to $294,121,787 as of June 30, 2026.
• The company's operations are dependent on obtaining additional funds through financing or monetization of intangible assets.
• The company sold its interest in NetCo Partners in May 2025 to settle a litigation funding liability.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to the company's continued precarious financial position, significant accumulated deficit, and ongoing reliance on external financing with no clear path to profitability.

Positives

• The company received $250,000 in cash proceeds from the issuance of common stock in March 2026.
• The sale of the NetCo investment in May 2025 successfully settled a significant litigation funding liability.
• Maturity dates for several notes payable have been extended to March 30, 2027, providing some short-term breathing room.

Negatives

• A net loss of $140,816 was reported for the six months ended June 30, 2026, a significant reversal from the net income of $2,546,625 in the prior year period.
• Current liabilities of $2,097,158 far exceed current assets of $64,687 as of June 30, 2026.
• The company has an accumulated deficit of $294,121,787 as of June 30, 2026.
• The company's ability to continue as a going concern is dependent on future financing and monetization of assets, raising substantial doubt.
• General and administrative expenses were $39,888 for the six months ended June 30, 2026, compared to $158,537 for the same period in 2025.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional funds through financing or monetization of intangible assets, and there is substantial doubt about its ability to do so.
• The company has a significant accumulated deficit and limited current assets relative to its liabilities.
• The company's former investment in NewStem was fully impaired and liquidated, with recovery dependent on future monetization of reverted intangible assets.
• The company has identified material weaknesses in its internal control over financial reporting, specifically related to insufficient resources for proper segregation of duties.

Future Outlook

The company's future operations are contingent on its ability to secure additional financing and successfully monetize its retained rights to intangible assets from the former NewStem technology. Management is actively pursuing these plans, but success is not assured.

Management Comments

• The company has prepared its financial statements for the six months ended June 30, 2026, assuming that we will continue as a going concern.
• Our continuation as a going concern is dependent upon improving our profitability and the continuing financial support from our shareholders as well as Yissums ability to successfully commercialize the License.
• We have identified material weaknesses in our internal control and procedures and internal control over financial reporting.

Industry Context

StockSavvy.ai notes that NovelStem International Corp. operates in a challenging environment for holding companies with limited operational assets. The biotech sector, where its former primary investment (NewStem) was focused, is capital-intensive and high-risk. The company's current strategy appears to be focused on asset monetization and fundraising rather than active business operations, which is a common but difficult path for companies in such situations.

Comparison to Industry Standards

• The company's current ratio (current assets to current liabilities) of approximately 0.03:1 as of June 30, 2026, is significantly below typical industry standards for healthy operating companies, indicating severe liquidity constraints.
• The substantial accumulated deficit of over $294 million is a critical concern, far exceeding typical benchmarks for companies in the development or holding stage, suggesting a prolonged period of unprofitability.
• The reliance on related-party debt and extensions of maturity dates is a common strategy for distressed companies but is not a sustainable long-term solution compared to established companies that can access public debt markets or equity offerings at favorable terms.

Related Party Transactions

• Notes payable to related parties, including the Executive Chairman and a shareholder, total $1,361,540 as of June 30, 2026.
• The Executive Chairman has advanced funds as an interim bridge loan to the Company for operating expenses.

Stakeholder Impact

• Shareholders face continued dilution risk from potential future equity raises and the lack of profitability.
• Creditors and lenders are exposed to the company's significant going concern risk, although maturity dates have been extended.
• Employees (if any) may be impacted by the company's uncertain financial future.

Next Steps

• Continue pursuing additional financing and fundraising efforts.
• Monetize the right to intangible assets held from NewStem.
• Explore potential merger or buyout transactions.
• Negotiate with debt holders to convert debt to equity.

Key Dates

Recommendation

The company exhibits severe liquidity issues, a substantial and growing accumulated deficit, and a lack of operational revenue. Its going concern status is in doubt, and its future hinges on uncertain financing and asset monetization. The negative financial trends and high risk profile warrant a sell recommendation.

Keywords

Quarterly Report, Financial Statements, Liquidity, Going Concern, Accumulated Deficit, Financing, Debt, Equity